Nicotinamide Cognitive Performance Randomized Trial: What the Evidence Says

Quick Answer

Nicotinamide Cognitive Performance Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• The decline of nicotinamide adenine dinucleotide (NAD) with aging may elevate risk of Alzheimer's disease and related neurocognitive disorders (ADRD) by impairing cellular energy metabolism and reducing cerebral blood flow. [Martens Christopher R (2025); evidence level 2]
• Perfusion of the left hippocampus increased with NR (pre: 51.7 ± 3.3; post: 58.0 ± 3.8 ml/min/100g) compared with placebo (pre: 55.6 ± 2.8; post: 51.7 ± 2.3 ml/min/100g; interaction= 0.033); however, this was not associated with the change in memory performance. [Martens Christopher R (2025); evidence level 2]
• Importantly, these biological changes manifest most meaningfully through declines in functional capacity, including reduced muscle strength, impaired metabolic regulation, diminished cognitive performance, and increased disease risk. [Kurtz Jennifer A. (2026); evidence level 4]
• This article aims to synthesize evidence from human studies evaluating dietary supplements that directly or indirectly modulate the recognized hallmarks of aging, such as mitochondrial dysfunction, oxidative stress, inflammation, and proteostasis. [Kurtz Jennifer A. (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For nicotinamide cognitive performance randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Martens Christopher R (2025). A phase‐II randomized controlled pilot and feasibility study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment. DOI: 10.1002/alz70861_108851. PMCID: PMC12724761. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12724761/
• Kurtz Jennifer A. (2026). Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits. DOI: 10.1007/s13668-026-00776-y. PMCID: PMC13233893. PMID: 42234350. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13233893/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.